Our results may also offer an explanation for why anti-angiogenesis therapy (anti-VEGFA; bevacizumab) generates clinical benefit in the treatment of metastatic colon cancer [31] but not when added to adjuvant chemotherapy following primary tumor resection [32]. Here, VEGFA is linked to neoplasm.